<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01132404</url>
  </required_header>
  <id_info>
    <org_study_id>C18002</org_study_id>
    <secondary_id>2009-017668-18</secondary_id>
    <nct_id>NCT01132404</nct_id>
  </id_info>
  <brief_title>Study in Men With Prostate Cancer to Assess the Safety, Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448</brief_title>
  <official_title>A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The phase 1 portion of this study is an open-label, multicenter, dose-escalation study of
      1-month depot TAK-448 in adult males with prostate cancer who are either on gonadotropin
      releasing hormone (GnRH) therapy or who might be eligible for GnRH therapy in the future. The
      phase 2 portion of this study is an open-label, multicenter, randomized study in men with
      prostate cancer that will confirm the testosterone- and prostate specific antigen (PSA)-
      lowering potential of up to 2 dose levels of 1-month depot TAK-448.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Developing new formulation of study drug. New study to open next year under a new protocol.
  </why_stopped>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For Phase 1 portion of study: to assess the safety and pharmacokinetics (PK) of TAK-448 in patients receiving a single dose of 1-month depot TAK-448</measure>
    <time_frame>3 months</time_frame>
    <description>Vital signs; 12-lead ECG; Clinical laboratory test results; Injection site-related skin reactions; Adverse Events (AEs)and Serious Adverse Events (SAEs); Maximum observed plasma concentration; Area under the plasma TAK-448 disposition curve; The time of last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>For Phase 2 portion of study: to assess the safety and PK of TAK-448 and effect of TAK-448 on serum testosterone concentrations in patients receiving repeated doses of 1-month depot TAK-448</measure>
    <time_frame>8 months</time_frame>
    <description>Vital signs; 12-lead ECG; Clinical laboratory test results; Injection site-related skin reactions; Adverse Events (AEs)and Serious Adverse Events (SAEs; Area under the plasma TAK-448 disposition curve; trough plasma concentration; Serum testosterone concentration; proportion of patients with serum concentration below castrate level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For Phase 1 portion of study: to assess the effect of 1-month depot TAK-448 on serum testosterone and luteinizing hormone (LH) concentrations in patients not receiving concomitant gonadotropin releasing hormone (GnRH) analog therapy</measure>
    <time_frame>3 months</time_frame>
    <description>Serum testosterone and LH concentrations; proportions of patients with serum testosterone concentrations below castrate-level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Phase 2 portion of study: to assess the effect of 1-month depot TAK-448 on serum prostate specific antigen (PSA) concentration</measure>
    <time_frame>8 months</time_frame>
    <description>Serum PSA concentration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>TAK-448 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Leuprorelin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprorelin</intervention_name>
    <description>Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months</description>
    <arm_group_label>Leuprorelin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-448</intervention_name>
    <description>Phase 1 portion of study:
Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site
Phase 2 portion of the study:
Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months</description>
    <arm_group_label>TAK-448 Dose 1</arm_group_label>
    <arm_group_label>TAK-448 Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Male 40 to 72 years of age

          -  Histologically-confirmed adenocarcinoma of the prostate having completed primary local
             treatment at least 6 months prior to screening

          -  Meet all laboratory evaluation values at screening as specified in protocol

          -  For phase 1 of the study only: Concurrent gonadotropin releasing hormone (GnRH)
             therapy with generally indolent or stable disease OR a potential candidate of GnRH at
             some time in the future. Patients with metastatic disease must be asymptomatic with
             only bone scan positive evidence of metastases. Patients with recurrent local disease
             will be asymptomatic without bladder, bowel or obstructive symptoms

          -  For phase 2 portion of the study only: evidence of progressive prostate cancer, which
             in the opinion of the referring physician and/or study investigator warrants the
             initiation of GnRH analog therapy. Such patients may have either elevated or rising
             PSA at least 6 months following primary local therapy (ies) or have evidence of
             metastatic disease not previously treated with GnRH analog therapy.

          -  Provision of informed consent and for the phase 1 portion of the study only, willing
             to participate with no expectation of therapeutic benefit

          -  Generally fit medical condition, with no acute or chronic medical conditions other
             than prostate cancer, affecting 2-year life expectancy

          -  Ability to understand and comply with protocol requirements

          -  Agreement to, even if surgically sterilized but not surgically castrated, practice
             effective barrier contraception OR abstain from heterosexual intercourse

          -  Suitable venous access for blood sampling

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in either
        the phase 1 or phase 2 portion of the study:

          -  Advanced or symptomatic metastatic prostate cancer requiring immediate GnRH or
             additional hormone therapy or requiring chemotherapy

          -  History of surgical castration

          -  History of nonskin cancer, other than prostate cancer, requiring active treatment
             within 2 years of screening

          -  History of cardiac surgery, within the previous 6 months or any planned elective
             surgeries, other than skin surgery, during the ensuing 6 months

          -  Compromise of bone marrow function that would reduce tolerance to repeated blood draws

          -  History of osteoporosis, unless actively controlled with treatment, or history of
             vertebral or femoral fracture within the past year

          -  History of seizures or currently on anticonvulsant medications

          -  History of major psychiatric illness (diagnosed psychosis or psychiatric illness
             requiring hospitalization)

          -  History of drug or significant alcohol abuse

          -  Participation in clinical trials or receipt of experimental therapy within 2 months of
             screening

          -  Serious infection within 14 days before first dose of study drug

          -  Known history of human immunodeficiency (HIV) infection, hepatitis B, or hepatitis C
             infection

          -  History of significant cardiovascular condition

        In addition, for the phase 2 portion of the study, patients must not have any of the
        following exclusion criteria:

          -  Participation in the phase 1 portion of the study

          -  Prior or current use of a GnRH analog or androgen receptor antagonist as first-line
             hormone therapy (other than as neoadjuvant/adjuvant use)

          -  History of use of GnRH analog or antagonist (as adjuvant or neoadjuvant therapy)
             within the 6 months prior to screening

          -  History of known or documented primary failure of GnRH analog therapy

          -  History of rising PSA or disease progression while on a GnRH analog or combined
             androgen blockade (CAB) therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Edouard Herriot, 5, Place d'Arsonval, Pavillon V - Urologie et chirurgie de la transplantation</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2010</study_first_submitted>
  <study_first_submitted_qc>May 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2010</study_first_posted>
  <last_update_submitted>January 26, 2012</last_update_submitted>
  <last_update_submitted_qc>January 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

